Cognito Therapeutics, a leader in technology-based treatments for neurodegenerative diseases, has announced a new publication in Frontiers in Neurology. The paper, titled “Spectris™ Treatment Preserves Corpus Callosum Structure in Alzheimer’s Disease,” showcases the potential of Spectris™ as a candidate for modifying the disease process in Alzheimer’s disease (AD).

Alzheimer’s disease is characterised by the loss of neurons and synapses and a decline in the structural integrity of white matter. While current treatments mainly focus on reducing amyloid protein build-up, they do not address the prevention of neurodegeneration directly.

Previous research suggested that Spectris therapy could help reduce cognitive and functional decline and limit brain atrophy in individuals with mild to moderate AD. Specifically, it was noted to help preserve white matter volume and myelin.

This recent study is the first to demonstrate that Spectris can preserve the corpus callosum in patients with mild to moderate Alzheimer’s disease. The corpus callosum is crucial for communication between the brain’s hemispheres and is vital for maintaining cognitive function.

Results from the six-month OVERTURE Phase 2 clinical trial (NCT03556280) indicated that patients receiving daily active treatment with Spectris showed preservation of the corpus callosum area. In contrast, the sham-treated group experienced significant atrophy. Notably, the treatment effects were visible as early as three months into the study.

After six months, participants in the active treatment group experienced a 0.20% preservation in the total corpus callosum area, while the sham group showed a 2.08% reduction, which was statistically significant (p<0.02). Specific regions of the corpus callosum, including the genu, rostrum, and splenium, also demonstrated marked preservation, consistently favouring the active group throughout the study.

The findings underscore that maintaining the structural integrity of the brain’s communication pathways could slow cognitive decline and improve daily functioning. This study supports the idea that Spectris may serve as a disease-modifying therapy for Alzheimer’s disease, offering an alternative to traditional drug-based treatments.

The upcoming HOPE pivotal study (NCT05637801) will further explore the effects of a 12-month daily Spectris treatment on function, cognition, and brain structure in patients with mild to moderate Alzheimer’s disease. It will also assess how preserving the integrity of the corpus callosum may influence cognitive function in Alzheimer's and other neurodegenerative disorders characterised by white matter abnormalities. More information about the pivotal study can be found at www.hopestudyforad.com.




Source: businesswire.com

Report Abuse